drugset
drugset / Trial / NCT05049083

A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

NCT05049083 ↗

Phase 1 Unknown 28 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

TThe study is being conducted to evaluate the relative bioavailability, pharmacokinetics and safety of different tablet processes of SHR2554 in healthy adult subjects.

Timeline

Start
2021-12-17
Primary completion
2022-01-06
Completion
2022-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR2554 Small molecule 350 mg —

Indications

lymphoma